Alembic Pharmaceuticals Receives US FDA Nod For Diltiazem Hydrochloride Capsules To Treat Hypertension
Alembic Pharmaceuticals Ltd. announced on Monday that it has received final approval from the US Food & Drug Administration for capsules to treat hypertension.
The company has received the abbreviated new drug application, or ANDA, approval for Diltiazem Hydrochloride extended-release capsules USP, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, as per an exchange filing.
Diltiazem hydrochloride extended-release capsules USPs are indicated for the treatment of hypertension. The capsules may be used alone or in combination with other antihypertensive medications. It is also indicated for the management of chronic stable angina and angina due to coronary artery spasm. Refer to the label for a detailed indication.
The approved ANDA is therapeutically equivalent to the reference listed drug product, Cardizem CD extended-release capsules, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg, of Bausch Health US, LLC.
Diltiazem hydrochloride extended-release capsules USP, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg have an estimated market size of $105.3 million for twelve months ending June 2024, according to IQVIA.
Alembic has a cumulative total of 218 ANDA approvals (191 final approvals and 27 tentative approvals) from the US FDA.
Shares of Alembic Pharmaceuticals closed 0.59% lower to Rs 1,032.05 apiece, compared to a 0.03% decline at the benchmark NSE Nifty 50.
It has risen 42.04% in the last 12 months and 35.90% on a year-to-date basis. The total traded volume in the day stood at 0.12 times its 30-day average. The relative strength index was at 33.17.
Seven out of the 16 analysts tracking the company have a 'buy' rating on the stock, six recommend a 'hold' and three suggest a 'sell,' according to Bloomberg data. The average of 12-month analyst price targets implies a potential upside of 10.4%.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.